Lung cancer tumor markers: Types and tests for NSCLC

If you’ve ever tried to assemble furniture without the instructions, you already understand why
tumor marker testing matters in non-small cell lung cancer (NSCLC). Sure, you can start
tightening random screws (aka “one-size-fits-all” treatment)… but it’s a lot smarter to find the
right diagram first. Tumor markersoften called biomarkersare that diagram.
They help your care team match the cancer’s “settings” to the treatments most likely to work.

In this guide, we’ll break down the most common NSCLC tumor markers, the tests used to find
them, and what your results may mean. We’ll also talk about the very real “waiting for results”
experiencebecause nothing tests patience like a lab report that’s taking a scenic route.

What “tumor markers” means in NSCLC (and why it’s not just a blood test)

Two big buckets: molecular biomarkers and classic blood tumor markers

The phrase tumor marker can mean different things depending on who’s talking:

• Molecular biomarkers (most important in NSCLC): Changes in tumor DNA or RNA
  (mutations, fusions, insertions) or protein signals (like PD-L1) that can predict which
  targeted therapy or immunotherapy is more likely to help.
• “Classic” blood tumor markers: Proteins found in blood that can sometimes rise
  with cancer (and also rise for non-cancer reasons). These are generally not the main
  decision-makers for NSCLC treatment the way molecular biomarkers are.

In modern NSCLC care, when someone says “tumor marker testing,” they usually mean
comprehensive biomarker testing on tumor tissue and/or a blood sample (liquid biopsy)
to look for actionable genetic changes and immune markersespecially in advanced disease.

Why tumor markers matter: treatment is no longer “one menu for everyone”

NSCLC isn’t one single disease. Two people can both have “lung adenocarcinoma,” but their tumors
may run on completely different molecular engines. Tumor markers help answer questions like:

• Is there a “driver” mutation we can target with a pill or infusion designed for that change?
• Is immunotherapy likely to help, and should it be combined with chemotherapy?
• Is a clinical trial a good fit based on a specific biomarker?
• After treatment, is the tumor developing a resistance mutation that changes the next step?

This is why guidelines and expert groups emphasize broad biomarker testingbecause finding the
right marker can dramatically change the treatment plan. In some situations, it even changes the
order of treatments (for example, waiting for results before starting certain therapies when it’s
safe to do so).

Key NSCLC tumor markers: the “usual suspects” your report may mention

There are many biomarkers in lung cancer research, but a core group shows up again and again in
real-world NSCLC care. Below are the ones you’ll most commonly hear about in
advanced or metastatic NSCLC, especially in non-squamous tumors.

EGFR

EGFR mutations (such as exon 19 deletions or L858R) can make tumors sensitive to
EGFR-targeted therapies. EGFR testing is a cornerstone of NSCLC biomarker panels, and it’s also
an example of why test quality mattersbecause specific EGFR changes can be linked to specific
drug options, including FDA-approved companion diagnostic pathways in certain contexts.

ALK (anaplastic lymphoma kinase)

ALK rearrangements (fusions) are classic NSCLC drivers. If present, they usually
point toward ALK-targeted therapy rather than starting with standard chemo right away.

ROS1

ROS1 rearrangements are less common than EGFR or ALK, but they’re highly actionable.
Many labs test ROS1 by next-generation sequencing (NGS), and some use confirmatory methods like
FISH depending on the situation and the assay.

KRAS (including KRAS G12C)

KRAS mutations are common in NSCLC, and specific subtypes like
KRAS G12C have targeted treatment options in the advanced setting. KRAS results can
influence both standard therapy decisions and clinical trial eligibility.

BRAF (often BRAF V600E)

BRAF mutations, especially V600E, can be actionable. Many biomarker
strategies include BRAF either as stand-alone testing or as part of a larger NGS panel.

MET (MET exon 14 skipping and MET amplification)

MET exon 14 skipping is an important actionable alteration in NSCLC. Some reports
also include MET amplification, which may matter for certain therapies or trials.

RET fusions

RET rearrangements are another actionable driver. Testing is commonly done through NGS,
which is well-suited to identifying gene fusions.

NTRK fusions

NTRK1/2/3 fusions are rare in NSCLC, but they’re important because they can open the
door to tumor-agnostic targeted therapies (treatments approved based on the fusion rather than
the cancer’s location).

HER2 (ERBB2)

In NSCLC, HER2 typically refers to ERBB2 mutations (not just the
HER2-overexpression story people may recognize from breast cancer). HER2 results can guide trial
options and, in some contexts, targeted approaches.

PD-L1 (protein expression)

PD-L1 is a protein measured on tumor cells (and sometimes immune cells) using
immunohistochemistry (IHC). The result is often reported as a tumor proportion score (TPS),
which can help guide immunotherapy decisionssuch as whether immunotherapy alone might be an option
in certain scenarios, or whether combination therapy is recommended.

Other markers you might see: MSI, TMB, and resistance changes

Some reports include tumor mutational burden (TMB) and microsatellite instability (MSI),
which are broader genomic features that can be relevant to immunotherapy in certain cancers and contexts.
You may also see “resistance” mutations on repeat testing after targeted therapy (for example, testing to
understand why a tumor that initially responded is growing again).

How are NSCLC tumor markers tested? A practical tour of the lab menu

1) Tissue biopsy testing

Tissue is still the gold standard for many biomarker questions because it provides tumor cells
directly for analysis. Tissue may come from a lung biopsy, lymph node biopsy, or a biopsy of a
metastatic site. Pathologists confirm the diagnosis and then perform or trigger (“reflex”) biomarker testing.

2) Next-generation sequencing (NGS): the “broad scan” approach

NGS panels can test many genes at once using tumor DNA (and sometimes RNA). This is
especially useful in NSCLC because actionable changes span mutations and fusions. Broad panels can reduce
the “one test at a time” delay and preserve precious tissue.

3) PCR-based tests: fast and focused

PCR (polymerase chain reaction) is often used for targeted, specific mutation checks
when there’s a known alteration of interest or limited tissue. It can be quick, but it doesn’t cover as much
territory as broad NGS.

4) FISH: a classic tool for rearrangements

FISH (fluorescence in situ hybridization) uses fluorescent probes to detect gene
rearrangements (like certain fusions). It’s been used for years in ALK and ROS1 testing and may appear as a
confirmatory method or when NGS isn’t available.

5) IHC: protein “staining” (including PD-L1)

IHC (immunohistochemistry) uses antibodies to stain proteins in tumor samples.
In NSCLC, it’s central for PD-L1 testing. It can also support screening for some fusions or
protein expression patterns, depending on the lab and biomarker.

6) Liquid biopsy (ctDNA): tumor clues from a blood sample

A liquid biopsy usually refers to testing blood for tumor-derived material such as
circulating tumor DNA (ctDNA). It can be incredibly helpful when tissue is hard to obtain,
when a quick answer is needed, or when doctors want to look for new mutations after treatment.

But liquid biopsy has a catch: if it finds an actionable mutation, that can be extremely useful.
If it finds nothing, it doesn’t always mean the tumor has no markersit may mean the tumor isn’t
shedding enough DNA into the bloodstream at that moment. In other words, a “negative” blood test can require
follow-up with tissue testing when possible.

Tissue vs. liquid biopsy: which one comes first?

In many real-world NSCLC cases, clinicians use both approaches strategically:

• Start with tissue when feasible because it confirms diagnosis, subtype, and provides strong
  material for broad biomarker testing.
• Add liquid biopsy when tissue is limited, the tumor is hard to reach, results are needed quickly,
  or the cancer has progressed and resistance is suspected.
• Use both to maximize the chance of finding actionable markers and to cross-check results in complex cases.

Reading your NSCLC biomarker report: common terms decoded

Lab reports can feel like they were written by a committee of robots who hate joy. Here are a few terms that
commonly trip people up:

• Actionable alteration: A change linked to an approved therapy or a strong clinical trial option.
• Fusion / rearrangement: Two genes joined together in a way that can drive cancer growth (often ALK, ROS1, RET, NTRK).
• Exon 14 skipping (MET): A specific RNA splicing change with targeted treatment implications.
• PD-L1 TPS (%): The percentage of tumor cells staining for PD-L1 (used to help guide immunotherapy decisions).
• Variant allele fraction (VAF): Roughly how much of the DNA sample carries a mutationuseful context, but not a standalone “severity” score.
• Insufficient tissue: Translation: “We tried, but the sample was too small or too low in tumor cells to run everything.”

Limitations and pitfalls: what tumor markers can’t do

Biomarker testing is powerful, but it’s not magic (sadly, no one has invented a “just fix it” button yet).
A few real limitations matter in NSCLC:

• Not every tumor has a known actionable marker. Sometimes the best approach is still immunotherapy, chemotherapy,
  radiation, surgery, or a clinical trial.
• Tumor heterogeneity is real. Different parts of a tumoror different metastasescan have different biomarker patterns.
  Small biopsies may miss some variation.
• Liquid biopsy can miss alterations. A negative ctDNA test doesn’t always rule out a target; it may reflect low DNA shedding.
• False positives can happen. Blood-based testing can sometimes pick up DNA changes unrelated to the tumor (for example, age-related blood cell changes),
  so clinicians interpret results in context.
• Turnaround time can delay decisions. Waiting for NGS results can feel endless, but starting the wrong treatment too early can also be risky in certain biomarker-defined situations.

Specific examples: how markers can change the plan

Here are three simplified “what this could look like” examples (every real case is more nuanced, but these show the idea):

• Example 1: A patient with metastatic lung adenocarcinoma has an EGFR exon 19 deletion.
  The team prioritizes an EGFR-targeted therapy rather than first-line immunotherapy alone, because the driver mutation strongly influences treatment selection.
• Example 2: A tumor shows an ALK fusion. The care plan shifts toward ALK-targeted therapy, and the team monitors for known resistance patterns if the cancer later progresses.
• Example 3: No actionable driver is found, but PD-L1 TPS is high.
  The treatment conversation focuses on immunotherapy-based options, with decisions shaped by stage, symptoms, pace of disease, and overall health.

Experience section: what the biomarker-testing journey often feels like (and how people navigate it)

Biomarker testing is science, but living through it is an experienceand many people describe it as a weird mix of
“thank goodness we have this technology” and “why does waiting feel like a full-time job?”

Experience #1: The “we need more tissue” plot twist.
It’s surprisingly common for an initial biopsy to confirm NSCLC but leave limited material for a full biomarker panel.
People often hear phrases like “insufficient tumor content” or “quantity not sufficient,” which can sound ominous.
Most of the time, it’s not a sign of worse cancerit’s a sign that biopsies are small by design, because doctors aim to
minimize risk. When this happens, many patients and caregivers describe a practical emotional swing: relief at having a diagnosis,
frustration at needing “one more thing,” and anxiety about delays. What helps most is a clear plan: Will the team do a repeat biopsy,
run liquid biopsy, or both? Having the next step scheduled quickly can reduce the feeling of being stuck in medical limbo.

Experience #2: The “my friend started treatment immediatelywhy am I waiting?” question.
In NSCLC, waiting for broad biomarker results can be medically important. Many patients describe the waiting period as
counterintuitive: you finally have an answer (“it’s cancer”), and then the next instruction is basically “now we wait for more answers.”
Clinicians often frame this as “the first treatment choice matters,” especially when a driver mutation could steer the plan toward a
targeted therapy. Some people cope by treating the wait like a mini project: they keep a list of pending tests, ask for the expected
turnaround time, and request that the pathology lab confirm the biomarker orders. It’s not about being difficult; it’s about making
sure the system doesn’t drop the ball when there are multiple handoffs.

Experience #3: Learning a new vocabulary overnight.
Many people say the hardest part isn’t the scienceit’s the sudden language upgrade. Overnight, you’re expected to understand
acronyms like EGFR, ALK, PD-L1, NGS, ctDNA, TPS, and “fusion” (which, in normal life, is something you do with smoothies).
A common strategy is to ask the care team for the “top three” markers that matter most in your specific case and the reason each one matters.
That keeps the conversation focused. Another helpful move: ask for a copy of the biomarker report and request a plain-language walkthrough.
People often feel more in control once the report stops looking like a secret message from a spy movie.

Experience #4: The relief of a matchand the complexity that can follow.
When testing finds an actionable driver mutation, many patients describe a sense of direction: “We have a target.”
That can be emotionally grounding. At the same time, it can bring new questions: How long do targeted therapies work?
What side effects should we watch for? What happens if resistance develops? Clinicians often explain this as a long-game strategy:
biomarker testing isn’t only for the first treatment decisionit can guide choices again later, including repeat testing if the cancer changes.
People who feel best supported often mention having a clear follow-up plan (“here’s what we’ll monitor, and here’s what we’ll do if we see progression”).

Experience #5: The caregiver’s perspectivebeing the “second brain.”
Caregivers frequently become the designated note-taker, appointment scheduler, and question organizer.
Many describe keeping a simple one-page “lung cancer dashboard”: diagnosis and stage, key biomarkers and results, current treatment,
side effects to watch, and contact numbers. This can be incredibly helpful during urgent visits or when seeing multiple specialists.
It also turns the chaos into something more manageablelike turning a pile of receipts into a spreadsheet (still annoying, but at least organized).

The biggest takeaway from these lived experiences is that biomarker testing isn’t just a lab stepit’s part of how people regain a sense of
structure in a scary time. Asking questions, tracking what’s pending, and understanding the basics of your markers can make the process feel less
like waiting in the dark and more like moving forward with a plan.

Bottom line

Tumor markers in NSCLC are less about a single “cancer blood test” and more about building a detailed molecular profile that can guide real treatment
choicesespecially in advanced disease. The most important markers include actionable driver alterations (like EGFR, ALK, ROS1, KRAS, BRAF, MET, RET,
NTRK, and HER2) and immune-related markers like PD-L1. Testing can be done on tissue, blood (liquid biopsy), or both, using tools like NGS, IHC, PCR,
and FISH.

If you’re going through this process, remember: it’s normal to feel overwhelmed by the vocabulary and the waiting. But biomarker testing is one of the
strongest ways modern NSCLC care turns “we have a diagnosis” into “we have a strategy.” Always discuss results and next steps with your oncology team,
who can interpret the findings in the context of your specific situation.